BindingDB logo
myBDB logout

23 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27994738 50 Sulfonamides as Selective NaEBI Amgen, Inc.
26985315 49 Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.EBI Xenon Pharmaceuticals, Inc.
25927480 36 Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.EBI Merck Research Laboratories
26101568 51 Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.EBI Pfizer Inc.
21300721 90 Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.EBI University of Oxford
25658507 218 Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.EBI Amgen Inc.
24601592 48 Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.EBI University College London
23121096 86 Ion channels as therapeutic targets: a drug discovery perspective.EBI Pfizer Inc.
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
18243692 85 Imidazopyridines: a novel class of hNav1.7 channel blockers.EBI Merck Research Laboratories
18176998 45 Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.EBI Abbott Laboratories
17804230 1 Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis.EBI Schering-Plough Research Institute
21106456 35 Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.EBI Merck Research Laboratories
20965738 78 Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.EBI Abbott Laboratories
20855211 91 Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.EBI Abbott Laboratories
18501613 31 Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.EBI Abbott Laboratories
17489575 7 Sodium channel blockers.EBI Purdue Pharma L.P.
17228859 86 Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.BDB Pfizer